These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22679698)

  • 21. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
    Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
    Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene rearrangements in radiation-induced thyroid carcinogenesis.
    Rabes HM
    Med Pediatr Oncol; 2001 May; 36(5):574-82. PubMed ID: 11340615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation induced thyroid cancer: fundamental and applied aspects.
    Tronko M; Bogdanova T; Voskoboynyk L; Zurnadzhy L; Shpak V; Gulak L
    Exp Oncol; 2010 Sep; 32(3):200-4. PubMed ID: 21403618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [BRAF gene mutation in thyroid cancer].
    Kopczyńska E; Junik R; Tyrakowski T
    Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on molecular biology of thyroid cancers.
    Omur O; Baran Y
    Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New molecular targeted therapies in thyroid cancer.
    Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
    Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
    Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Thyroid carcinoma].
    Namba H; Izumi M
    Gan To Kagaku Ryoho; 1991 Jan; 18(1):22-9. PubMed ID: 1987898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of ancillary methods for diagnosis, prognosis and targeted therapy in thyroid pathology.
    Bozec A; Ilie M; Lassalle S; Hofman V; Benaim G; Long E; Santini J; Hofman P
    Curr Med Chem; 2013; 20(5):639-54. PubMed ID: 23298138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
    Kelil T; Keraliya AR; Howard SA; Krajewski KM; Braschi-Amirfarzan M; Hornick JL; Ramaiya NH; Tirumani SH
    Radiographics; 2016; 36(5):1478-93. PubMed ID: 27618325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine tumours: progressive metastatic medullary thyroid carcinoma: first- and second-line strategies.
    Links TP; Verbeek HH; Hofstra RM; Plukker JT
    Eur J Endocrinol; 2015 Jun; 172(6):R241-51. PubMed ID: 25627652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Translational Challenges in Thyroid Cancer.
    Hernando J; Ros J; Arroyo A; Capdevila J
    Curr Med Chem; 2020; 27(29):4806-4822. PubMed ID: 32056516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy.
    Yip L
    J Surg Oncol; 2015 Jan; 111(1):43-50. PubMed ID: 25155423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA methylation alterations as therapeutic prospects in thyroid cancer.
    Zhang K; Li C; Liu J; Tang X; Li Z
    J Endocrinol Invest; 2019 Apr; 42(4):363-370. PubMed ID: 29992502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research advances in molecular pathogenesis of thyroid cancer].
    Aleha M; Meng QB; Yu JC; Kang WM; Cao ZJ; Tian SB
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):382-5. PubMed ID: 23987483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies.
    Agarwal R; Liebe S; Turski ML; Vidwans SJ; Janku F; Garrido-Laguna I; Munoz J; Schwab R; Rodon J; Kurzrock R; Subbiah V;
    Discov Med; 2015 Feb; 19(103):101-8. PubMed ID: 25725224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What should a surgeon known about genetic background of thyroid cancer.
    Bavor P; Peková B; Sýkorová V; Bendlová B; Hoch J
    Rozhl Chir; 2020; 99(11):481-486. PubMed ID: 33445945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Progress in research of thyroid carcinoma related gene mutation and epigenetics].
    Zheng WH; Gong WW; Lu F; Yu M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Nov; 38(11):1579-1583. PubMed ID: 29141353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Considerations in the Treatment of Thyroid Carcinoma.
    Hattum CJ; Elsey RJ; Meissner T; Spanos WC
    JCO Oncol Pract; 2024 Jul; 20(7):873-875. PubMed ID: 38621192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.